GI Symposium Colorectal Cancer Spotlight

Zev A. Wainberg, MD, discusses the impact of the COVID-19 on the colorectal cancer field specifically in terms of clinical trial research.

John L. Marshall, MD, discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology.

Tanios S. Bekaii-Saab, MD, discusses genetic testing and emerging precision medicine strategies in the field of colorectal cancer.

The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity among patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild-type, according to findings from a phase 2 LCCC1632 study.

John H. Strickler, MD, discusses dosing of regorafenib in patients with colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses factors that should be considered when deciding on treatment for a patient with metastatic colorectal cancer.

Zev A. Wainberg, MD, explains the importance of having a chemotherapy-free option available for patients with colorectal cancer.

The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.

The frontline combination of trifluridine/tipiracil in combination with bevacizumab demonstrated an overall survival benefit compared with capecitabine and bevacizumab as treatment of patients with unresectable metastatic colorectal cancer who are not eligible for a standard chemotherapy regimen, resulting in a difference of almost 5 months, according to the final analysis of the phase 2 TASCO1 trial.

The use of pembrolizumab monotherapy upfront significantly improved progression-free survival while demonstrating superior safety, compared with chemotherapy, in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

Treatment with the multi-target tyrosine kinase inhibitor anlotinib led to a significant improvement in progression-free survival along with a tolerable and manageable safety profile in Chinese patients with refractory metastatic colorectal cancer. according to results from the phase 3 ALTER0703 trial.

Immunotherapy with pembrolizumab in combination with capecitabine-based chemotherapy and the VEGF inhibitor bevacizumab, appeared tolerable as treatment of patients with microsatellite stable metastatic colorectal cancer, showing a safety profile that was expected with the drug, results from a phase 2 study show.